You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The legal imperative for treating rare disorders
|
|---|---|
| Published in |
Orphanet Journal of Rare Diseases, September 2013
|
| DOI | 10.1186/1750-1172-8-135 |
| Pubmed ID | |
| Authors |
Hanna I Hyry, Jonathan CP Roos, Jeremy Manuel, Timothy M Cox |
| Abstract |
Life-saving orphan drugs are some of the most expensive medicines. European Union governments aim to accommodate their provision within stretched healthcare budgets but face pressure to reduce funding of such treatments. Patients struggle to retain or gain access to them as their special status is questioned, causing distress and in some cases, fears of premature death. In the UK and EU reimbursement and pricing model of drugs, and orphan drugs in particular, is being re-evaluated. |
X Demographics
The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 29% |
| United Kingdom | 2 | 14% |
| Mexico | 1 | 7% |
| Canada | 1 | 7% |
| Spain | 1 | 7% |
| Unknown | 5 | 36% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 93% |
| Scientists | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Indonesia | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 61 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 21 | 33% |
| Student > Ph. D. Student | 9 | 14% |
| Student > Master | 7 | 11% |
| Student > Bachelor | 5 | 8% |
| Other | 3 | 5% |
| Other | 9 | 14% |
| Unknown | 9 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 32% |
| Social Sciences | 9 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 11% |
| Biochemistry, Genetics and Molecular Biology | 4 | 6% |
| Economics, Econometrics and Finance | 4 | 6% |
| Other | 10 | 16% |
| Unknown | 9 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 January 2014.
All research outputs
#4,139,298
of 25,373,627 outputs
Outputs from Orphanet Journal of Rare Diseases
#567
of 3,105 outputs
Outputs of similar age
#34,262
of 209,239 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#7
of 56 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,105 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 209,239 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 56 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.